Strong Revenue Growth in Q3 2024
Swedish Orphan Biovitrum AB (publ) (SOBI) has reported remarkable results for the third quarter of 2024, showcasing a significant increase in revenue compared to the previous year. The company's total revenue surged by 33 percent and an impressive 39 percent when considering constant exchange rates, reaching SEK 6,894 million, up from SEK 5,168 million.
Performance by Business Segment
Within the company's haematology sector, revenue grew by 18 percent at constant exchange rates, totaling SEK 4,000 million. This growth can be attributed largely to a substantial rise in sales of Doptelet, which generated SEK 1,039 million in revenue, a notable increase from SEK 650 million last year. Other contributors include Aspaveli/Empaveli, with sales of SEK 270 million, and the newly launched Altuvoct, which accounted for SEK 129 million in sales.
Immunology Sector Shows Exceptional Growth
The immunology segment exhibited even more impressive results, with revenue skyrocketing by 96 percent at constant exchange rates, amounting to SEK 2,583 million, compared to SEK 1,400 million in the previous year. A significant portion of this growth derived from Beyfortus royalties, which alone contributed SEK 1,478 million to revenue, along with Kineret sales of SEK 699 million.
Strategic Portfolio Performance
Revenue generated from Sobi's strategic portfolio of medicines increased by 113 percent at constant exchange rates, totaling SEK 3,830 million, a considerable rise from SEK 1,924 million. These results highlight the company's successful focus on developing and launching innovative treatments that meet unmet medical needs.
Financial Metrics and Projection
Sobi's adjusted EBITA margin was recorded at 43 percent, a significant improvement from 30 percent last year. The EBITA reached SEK 2,923 million, translating to a margin of 42 percent, up from 28 percent previously. Their earnings per share (EPS) before dilution increased correspondingly to SEK 4.27, compared to SEK 0.30 in the same quarter last year. Moreover, cash flow from operating activities also saw a rise, standing at SEK 1,201 million.
Future Outlook for 2024
As Sobi looks ahead, the outlook for 2024 has been updated to reflect confidence in continued growth. The company anticipates revenue to increase by a mid-teens percentage under constant exchange rates. Additionally, they expect the adjusted EBITA margin to remain in the mid-30s percentage of revenue.
Ongoing Clinical Developments
Recently, Sobi and Apellis Pharmaceuticals have made progress with their Phase 3 VALIANT study concerning pegcetacoplan for treating conditions like C3G and primary IC-MPGN, further solidifying Sobi's commitment to expanding its robust pipeline and offering innovative solutions.
Engagement with Investors and Analysts
To foster transparency and keep stakeholders informed, Sobi invites investors, analysts, and media representatives to participate in a conference call to discuss these results in detail. The call will include a comprehensive presentation followed by a Q&A session, encouraging active participation and feedback from attendees.
Frequently Asked Questions
What was Sobi's total revenue for Q3 2024?
Total revenue for Q3 2024 was SEK 6,894 million, representing a 33% increase.
How much did the haematology segment grow?
The haematology revenue grew by 18% at constant exchange rates, totaling SEK 4,000 million.
What are Sobi's future revenue growth expectations?
Sobi anticipates revenue growth in the mid-teens percentage range for 2024.
Which products contributed to the immunology sector’s growth?
The immunology sector’s growth was largely driven by Beyfortus and Kineret, accounting for significant revenue increases.
How can investors participate in the conference call?
Investors can join the conference call using the provided dial-in details on Sobi's official website.
